In one of the biggest breakthroughs in schizophrenia research in recent times, Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to transform global schizophrenia research and open new avenues for developing targeted immune cell therapies.
One in every 100 Australians lives with schizophrenia. No single cause of schizophrenia has been identified, and this has prevented the development of a cure. The current treatments for schizophrenia are designed to suppress symptoms rather than target underlying causes of the disorder. These drugs only partially relieve symptoms and can produce unwanted side effects.
To recognise the significance of this discovery Professor Shannon Weickert says you first need to understand most scientists have had a long held belief that immune cells were independent from the brain pathology in psychotic illnesses.
“In our study, we challenged this assumption that immune cells were independent of the brain in psychiatric illness and made an exciting discovery. We identified immune cells as a new player in the brain pathology of schizophrenia,” said Professor Shannon Weickert.
Current schizophrenia research has focused on the status of three brain cells: the neurons; the glial cells, which support the neurons; and the endothelial cells, which coat the blood vessels. Employing new molecular techniques allowed Professor Shannon Weickert and her team to identify the presence of a fourth cell, the macrophage, a type of immune cell in the brain tissue of people with schizophrenia who show high levels of inflammation.
Professor Shannon Weickert said immune cells have previously been ignored as they had long been viewed simply as travelers just thought to be passing by, undertaking surveillance work. They have never been a suspect until now.
“To find immune cells along the blood brain barrier in increased amounts in people with schizophrenia is an exciting discovery. It suggests immune cells themselves may be producing these inflammatory signals in the brains of people living with schizophrenia,” said Professor Shannon Weickert.
“We have observed in people with schizophrenia, the glial cells, one of the local residents, become inflamed and produce distress signals which change the status of the endothelial cells.
“We think this may cause the endothelial cells to extend sticky tentacles, so when the immune cells travel by some are captured. These cells may transmigrate across the blood brain barrier entering the brain in greater amounts in some people with schizophrenia compared to people without the disorder.”
This discovery shows that specific immune cells are in the brains of some people with schizophrenia in close enough proximity to the neurons to do damage.
Professor Peter Schofield, CEO of NeuRA said this innovative new research has the ability to alter the way in which we may be able to diagnose and treat schizophrenia.
“This breakthrough demonstrates the value of the NSW Government’s support for Professor Shannon Weickert as NSW Chair of Schizophrenia Research, which has delivered new insights that the community seeks,” said Professor Schofield.
Professor Shannon Weickert is encouraging a cross-collaborative approach between neuroscientists and immunologists globally, to work together to develop treatments targeting this abnormal immune pathology of schizophrenia.
“This opens whole new avenues for therapy, because it suggests that the pathology of schizophrenia could be within the immune cells and the immune cells could be contributing to the symptoms of schizophrenia,” said Professor Shannon Weickert.
Professor Shannon Weickert is uniquely motivated in her work, with her twin-brother being diagnosed with schizophrenia when he was 17 years old.
Learn more: Schizophrenia breakthrough
The Latest on: Schizophrenia
via Google News
The Latest on: Schizophrenia
- Levels of gene-expression-regulating enzyme altered in brains of people with schizophrenia on December 14, 2018 at 12:15 pm
Using the PET scan tracer Martinostat, Mass. General Hospital investigators found that expression of HDAC epigenetic enzymes (red) is higher in a brain region (arrows) known to be important for ... […]
- Understanding schizophrenia on December 14, 2018 at 11:52 am
Schizophrenia affects about 1% of the world’s population and is one of the most feared and misunderstood mental health health problems that a person can experience. Images of psychiatric hospitals, se... […]
- Genomic data from 2000 human brains could reveal roots of schizophrenia, autism, and other neurological disorders on December 13, 2018 at 2:03 pm
More than 2000 human brains stored in tissue banks are giving up their genetic secrets. Genome scans have already revealed hundreds of locations where DNA tends to differ between people with and witho... […]
- Sunovion, PsychoGenics nondopamine schizophrenia drug meets phase 2 endpoint on December 13, 2018 at 6:06 am
Sunovion Pharmaceuticals and PsychoGenics unveiled positive phase 2 results for a new schizophrenia treatment that does not bind to the brain’s dopamine receptors. While its exact mechanism of action ... […]
- Vitamin D and Schizophrenia; 007 and Alcohol Abuse on December 12, 2018 at 2:49 pm
Newborns with vitamin D deficiency may face higher risk for schizophrenia later in life, a Danish case-control study indicated. "The next step is to conduct randomized clinical trials of vitamin D sup... […]
- The NIMH Research Domain Criteria Initiative and Comorbidity in Schizophrenia: Research Implications on December 12, 2018 at 11:10 am
A particular challenge to traditional diagnostic classifications is psychiatric comorbid presentations. In the case of schizophrenia, the DSM-5 considers comorbid symptoms as part of another diagnosis ... […]
- FDA to Review Lumateperone for Treatment of Schizophrenia on December 11, 2018 at 1:30 pm
Intra-Cellular Therapies announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for lumateperone (ITI-007) for the treatment of schizophrenia. Lum... […]
- What to Know About Schizophrenia—a Chronic, Misunderstood Mental Illness on December 11, 2018 at 9:46 am
Schizophrenia is a serious mental illness that alters how a person feels, what they see, and how they behave. It’s a chronic condition, and there's no cure for it. However, many people with schizophre... […]
- Study: Newborns with Vitamin D Deficiency Have Higher Risk of Later Schizophrenia on December 11, 2018 at 4:32 am
A study published in the December 6, 2018 issue of the journal Scientific Reports found newborns with vitamin D deficiency had a 44% increased risk of being diagnosed with schizophrenia as adults comp... […]
via Bing News